MAPT and Alzheimer disease: In the past, treatment strategies targeting amyloid or tau toxicity such as β-secretase inhibition, γ-secretase modulators, anti-Aβ antibodies and tau-targeted vaccines all failed in Phase 2 or 3 of clinical trials of AD [54].